ATE252909T1 - Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium - Google Patents

Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium

Info

Publication number
ATE252909T1
ATE252909T1 AT98930729T AT98930729T ATE252909T1 AT E252909 T1 ATE252909 T1 AT E252909T1 AT 98930729 T AT98930729 T AT 98930729T AT 98930729 T AT98930729 T AT 98930729T AT E252909 T1 ATE252909 T1 AT E252909T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
preparation containing
low solubility
containing peptides
physiological medium
Prior art date
Application number
AT98930729T
Other languages
English (en)
Inventor
Peter Richardson
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97108593A external-priority patent/EP0880968A1/de
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE252909T1 publication Critical patent/ATE252909T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT98930729T 1997-05-28 1998-05-26 Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium ATE252909T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108593A EP0880968A1 (de) 1997-05-28 1997-05-28 In physiologischem Medium schwerlösliche pharmazeutische Peptidezusammensetzungen
EP97121246A EP0880969A1 (de) 1997-05-28 1997-12-03 Im physiologischem Medium schwerlösliche pharmazeutische Peptidezusammensetzungen
PCT/EP1998/003079 WO1998053844A1 (en) 1997-05-28 1998-05-26 Pharmaceutical compostions of peptides having low solubility in physiological medium

Publications (1)

Publication Number Publication Date
ATE252909T1 true ATE252909T1 (de) 2003-11-15

Family

ID=26145485

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930729T ATE252909T1 (de) 1997-05-28 1998-05-26 Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium

Country Status (26)

Country Link
US (1) US6331520B1 (de)
EP (2) EP0880969A1 (de)
JP (1) JP2002502384A (de)
KR (1) KR100552546B1 (de)
CN (1) CN1159062C (de)
AR (1) AR012868A1 (de)
AT (1) ATE252909T1 (de)
AU (1) AU743152B2 (de)
BG (1) BG64668B1 (de)
BR (1) BR9809708A (de)
CA (1) CA2291765A1 (de)
CZ (1) CZ298825B6 (de)
DE (1) DE69819322T2 (de)
DK (1) DK0984788T3 (de)
EA (1) EA002227B1 (de)
EE (1) EE04001B1 (de)
ES (1) ES2210772T3 (de)
IL (2) IL133176A0 (de)
NO (1) NO323697B1 (de)
NZ (1) NZ500777A (de)
PL (1) PL192647B1 (de)
PT (1) PT984788E (de)
SI (1) SI0984788T1 (de)
SK (1) SK284640B6 (de)
TR (1) TR199902865T2 (de)
WO (1) WO1998053844A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343186B2 (en) 2004-04-06 2013-01-01 Arthrex, Inc. Fully threaded suture anchor with transverse anchor pin
EP1064934A1 (de) 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. Gefriergetrocknete GRF-enthaltende Arzneimittel
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
US20040229334A1 (en) * 2003-05-15 2004-11-18 Mendoza Christine B. Process for manufacture of nematode-extracted anticoagulant protein (NAP)
MX2009010675A (es) * 2007-04-04 2009-10-23 Theratechnologies Inc Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
KR102261301B1 (ko) * 2012-10-12 2021-06-07 로레알 적어도 하나의 하이드로트로프 및 적어도 하나의 활성제을 포함하는 화장용 조성물
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
US9669242B2 (en) * 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
CA3014406A1 (en) 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia,and hormone-related tumors
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
EP0374120A3 (de) * 1988-12-13 1991-07-31 Monsanto Company Zusammensetzung mit kontrollierter Wirkstoffabgabe von Polypeptiden
US5382574A (en) * 1989-12-21 1995-01-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
IL102857A (en) * 1991-08-26 1997-02-18 Abbott Lab Compositions for the sublingual or buccal administration of therapeutic agents which are degraded upon oral administration
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
US5446025A (en) * 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
JP2944419B2 (ja) * 1993-05-10 1999-09-06 ノバルティス アクチエンゲゼルシャフト 持続性遊離組成物中の薬理学的活性成分の安定
TW280770B (de) * 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
WO1996010417A1 (en) * 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제

Also Published As

Publication number Publication date
SK284640B6 (sk) 2005-08-04
HK1029928A1 (en) 2001-04-20
DK0984788T3 (da) 2004-03-08
ES2210772T3 (es) 2004-07-01
EE9900545A (et) 2000-06-15
SK159799A3 (en) 2000-07-11
IL133176A0 (en) 2001-03-19
JP2002502384A (ja) 2002-01-22
PT984788E (pt) 2004-01-30
EP0880969A1 (de) 1998-12-02
AU8106298A (en) 1998-12-30
US6331520B1 (en) 2001-12-18
AR012868A1 (es) 2000-11-22
EA002227B1 (ru) 2002-02-28
KR100552546B1 (ko) 2006-02-14
NO995763L (no) 1999-11-24
NZ500777A (en) 2001-09-28
NO995763D0 (no) 1999-11-24
EP0984788B1 (de) 2003-10-29
BG103884A (en) 2000-07-31
BR9809708A (pt) 2000-07-11
CN1263469A (zh) 2000-08-16
EP0984788A1 (de) 2000-03-15
KR20010012253A (ko) 2001-02-15
CA2291765A1 (en) 1998-12-03
CN1159062C (zh) 2004-07-28
PL336982A1 (en) 2000-07-31
EA199901089A1 (ru) 2000-06-26
SI0984788T1 (en) 2004-02-29
AU743152B2 (en) 2002-01-17
CZ298825B6 (cs) 2008-02-20
PL192647B1 (pl) 2006-11-30
NO323697B1 (no) 2007-06-25
WO1998053844A1 (en) 1998-12-03
DE69819322D1 (de) 2003-12-04
CZ423199A3 (cs) 2000-05-17
BG64668B1 (bg) 2005-11-30
TR199902865T2 (xx) 2000-05-22
DE69819322T2 (de) 2004-07-29
IL133176A (en) 2006-08-01
EE04001B1 (et) 2003-04-15

Similar Documents

Publication Publication Date Title
DE69819322D1 (de) Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
EP1246608A4 (de) PHARMAZEUTISCHE ZUBEREITUNGEN ZUR VERABREICHUNG VON WIRKSTOFFEN MIT GERINGER WASSERLöSLICHKEIT
ATE230611T1 (de) Pharmazeutische zusammensetzungen mit plasmaproteinen
DE69622735D1 (de) Lyophilisierte stabile pharmazeutische formulierung
DE69525148D1 (de) Pharmazeutische formulierung
DE69626397D1 (de) Darifenacin enthaltende pharmazeutische zubereitungen
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
DE69828895D1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
DE69325408D1 (de) Pharmazeutische Zubereitung in wässriger Suspensionsform
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
DE59813619D1 (de) Ascorbinsäurederivate enthaltende kosmetische und pharmazeutische Zubereitungen
ATE432707T1 (de) Pharmazeutische zubereitung
DE69827357D1 (de) Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung
DE69732649D1 (de) Heteroarylsulfonamidderivate und diese enthaltende pharmazeutische zubereitungen
DE59903028D1 (de) Levothyroxin natrium enthaltende pharmazeutische zubereitung
DE59910298D1 (de) Pharmazeutische levothyroxinzubereitung
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
DE69427977D1 (de) Ein physiologisch-aktives peptid enthaltendes vaginales präparat
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
ATE208364T1 (de) A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
DE69800970D1 (de) Pyridinderivate und sie enthaltende pharmazeutische zubereitungen
DE69122229D1 (de) Penciclovir enthaltende pharmazeutische formulierung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0984788

Country of ref document: EP

REN Ceased due to non-payment of the annual fee